Open-label Roll-Over Study to Assess the Long-term Safety and Efficacy of Ruxolitinib in Subjects With Myelofibrosis

Trial Profile

Open-label Roll-Over Study to Assess the Long-term Safety and Efficacy of Ruxolitinib in Subjects With Myelofibrosis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Myelofibrosis
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 30 Sep 2016 Status changed from not yet recruiting to recruiting.
    • 10 Aug 2016 Planned primary completion date changed from 1 Aug 2019 to 1 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top